BioPharmSignal logoBioPharmSignal

Biotech News

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

Lisata Therapeutics (LSTA)Lisata TherapeuticsFinancing

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is

Related news

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

IMTXImmatics2026-08-25 11:00 EST

Immatics Announces $150 Million Underwritten Offering

LSTALisata Therapeutics2026-08-04 11:00 EST

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

TEVATeva Pharmaceutical Industries2026-09-07 07:53 EST

Teva Announces Launch of Offering of Senior Notes

CGEMCullinan Therapeutics, Inc.2026-09-10 17:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

View all latest news

Lisata Therapeutics

Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.

Recent company news

LSTALisata Therapeutics2026-09-17 13:27 EST

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

LSTALisata Therapeutics2026-08-04 11:00 EST

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

LSTALisata Therapeutics2026-06-10 12:00 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

LSTALisata Therapeutics2026-03-06 23:15 EST

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

LSTALisata Therapeutics2026-01-27 13:00 EST

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Stock data

Close
1.74 USD
Market cap
31.69M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States